SEC Form 4 · accession 0001209191-17-059815

GENOMIC HEALTH INC · GHDX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Commercial Officer

Period of report

Nov 1, 2017

Accepted (ET)

Nov 8, 2017 · 5:29 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001131324

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1	Nov 1, 2017	M	2,410	$17.33	A	32,195	D
Common Stock^F1	Nov 1, 2017	M	1,497	$17.33	A	33,692	D
Common Stock^F2,F3,F4,F1	Nov 1, 2017	S	2,410	$32.5723	D	31,282	D
Common Stock^F2,F4,F5,F1	Nov 1, 2017	S	1,497	$32.5754	D	29,785	D
Common Stock^F2,F4,F6,F1	Nov 1, 2017	S	1,710	$32.5945	D	28,075	D
Common Stock^F1	Nov 2, 2017	M	824	$17.33	A	28,899	D
Common Stock^F1	Nov 2, 2017	M	100	$17.33	A	28,999	D
Common Stock^F2,F4,F7,F1	Nov 2, 2017	S	824	$32.5083	D	28,175	D
Common Stock^F2,F8,F1	Nov 2, 2017	S	100	$32.50	D	28,075	D
Common Stock^F2,F4,F9,F1	Nov 2, 2017	S	455	$32.5066	D	27,620	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Owned after	D/I
Employee Stock Option (right to buy)^F10	$17.33	Nov 1, 2017	M	2,410	D	—	Dec 4, 2018	Common Stock	4,590	D
Employee Stock Option (right to buy)^F10	$17.33	Nov 1, 2017	M	1,497	D	—	Dec 4, 2018	Common Stock	3,093	D
Employee Stock Option (right to buy)^F10	$17.33	Nov 2, 2017	M	824	D	—	Dec 4, 2018	Common Stock	2,269	D
Employee Stock Option (right to buy)^F10	$17.33	Nov 2, 2017	M	100	D	—	Dec 4, 2018	Common Stock	2,169	D

F1Includes an aggregate of 17,374 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
F10The option became exercisable as to 25% of the shares on December 4, 2009, and became exercisable as to 1/48th of the shares each full month thereafter.
F2These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on June 8, 2017.
F3Represents weighted average sale price. Actual sale prices ranged from $32.50 to $32.79.
F4Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
F5Represents weighted average sale price. Actual sale prices ranged from $32.50 to $32.68.
F6Represents weighted average sale price. Actual sale prices ranged from $32.50 to $32.85.
F7Represents weighted average sale price. Actual sale prices ranged from $32.50 to $32.57.
F8Represents actual sale price.
F9Represents weighted average sale price. Actual sale prices ranged from $32.50 to $32.54.